EA Pharma Co., Ltd.
EA Pharma Co., Ltd. (President, Yuji Matsue; Headquarters, Tokyo, Japan) (hereinafter “EA Pharma”) has signed a license agreement with Dr. Falk Pharma GmbH (Managing Directors, Roland Greinwald, Philipp Argast and Susanne Höppner; Headquarters, Freiburg, Germany) (hereinafter “Dr. Falk Pharma”) to grant EA Pharma the rights to develop, manufacture and commercialize nor-Ursodeoxycholic Acid (norUDCA), Dr. Falk Pharma’s developing new liver disease treatment, in Japan.
Under the license agreement, EA Pharma develops norUDCA for treatment of primary sclerosing cholangitis (PSC) and non-alcoholic steatohepatitis (NASH) in Japan. Once the marketing approval is obtained, EA Pharma will exclusively commercialize norUDCA in Japan. EA Pharma pays an upfront payment, milestone payments and royalties to Dr. Falk Pharma under the license agreement.
norUDCA is a novel liver disease treatment that Dr. Falk Pharma has been developing for treatment of PSC and non-alcoholic fatty liver disease (NAFLD). In Phase II clinical trial in patients with PSC conducted in European countries, improvements in liver function parameters including alkaline phosphatase were demonstrated. PSC is one of the designated intractable diseases in Japan. PSC can progress to non-compensated liver cirrhosis, but there exists no effective medicine indicated for PSC at this moment. Development of new treatment to suppress disease progression of PSC has been awaited. Further, in Phase II clinical trial in patients with NAFLD conducted in European countries, improvements in liver fat content and liver stiffness in addition to alanine aminotransferase, which is a liver damage parameter, were confirmed. The results suggest that norUDCA can be available as a treatment of NASH. EA Pharma and Dr. Falk Pharma will collaborate under the license agreement to quickly obtain the marketing approval of norUDCA in Japan.
As a gastrointestinal specialty pharma, EA Pharma positions “inflammatory bowel disease”, “liver and pancreatic diseases”, “gastrointestinal function and symptoms improvement”, and “gastrointestinal mucosal protection” and “supports for gastrointestinal endoscopy/surgery” as its key areas to provide new solutions for unmet medical needs. EA Pharma expects that development of norUDCA as a new treatment of liver disease can contribute to fulfilment of unmet medical needs of patients with liver diseases for which no effective treatment exist at this moment.
End
| More Information |
3. About Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
If diagnosed with fatty liver by histology or diagnostic imaging regardless of no alcohol drinking habit, the condition is called non-alcoholic fatty liver disease (NAFLD). In 80-90% of patients with NAFLD, the disease remains a simple fatty liver for long years. But, in 10-20%, the disease gradually progresses to involve liver cirrhosis or liver cancer. Among the fatty liver disease of non-alcohol cause, if the fatty liver disease involves inflammation and fibrosis, the condition is called NASH, which can progress to liver cirrhosis or liver cancer. It is reported that the disease prevalence of NAFLD is 9-30% and the total number of patients for NAFLD in Japan is more than 10,000,000, many in the middle age in male and the elderly in female. In addition, the disease prevalence of NASH is estimated to be 3-5%3) .With increase of patients with obesity or metabolic syndrome, the patient number of NAFLD and NASH can increase. At this point in time, however, there exists no medicine indicated for NAFLD and NASH available in the market.
4. About EA Pharma Co., Ltd.
EA Pharma, a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 years’ history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, logistics and sales & marketing.
For more information on EA Pharma Co., Ltd., please see http://www.eapharma.co.jp/en/
5. About Dr. Falk Pharma GmbH
Dr. Falk Pharma GmbH is one of the leading companies worldwide in gastroenterology with its products being sold in more than 60 countries. Its pharmaceuticals are used successfully to treat inflammatory bowel disease, cholestatic liver disease, irritable bowel syndrome, constipation, and for colon cleansing prior to colonoscopies. The Falk Foundation, which is associated with the company, provides medical information via international symposia, forums, postgraduate courses and literature services. Over the past 45 years the Falk Foundation has sponsored more than 200 international Falk symposia and workshops in which over 100,000 researchers and physicians from 110 countries have come together to advance knowledge in gastroenterology and hepatology.
Rectabul®2 mg Rectal Foam 14 Doses (budesonide rectal foam), for which EA Pharma obtained marketing approval in Japan in November 2017, is an ulcerative colitis treatment in-licensed from Dr. Falk Pharma.
For more information on Dr. Falk Pharma GmbH, please see https://www.drfalkpharma.de